SIGA Technologies has been granted a patent for polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-benzamide for treating Orthopoxvirus infections. The method involves administering a specific polymorph Form I with defined X-ray powder diffraction pattern peaks. GlobalData’s report on SIGA Technologies gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on SIGA Technologies, Peptide pharmacophores was a key innovation area identified from patents. SIGA Technologies's grant share as of February 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of orthopoxvirus infections using polymorph form i of st-246
A recently granted patent (Publication Number: US11890270B2) discloses a method for treating Orthopoxvirus infections and eczema vaccinatum by administering a specific polymorph Form I of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-benzamide (ST-246). This polymorph Form I exhibits a distinct X-ray powder diffraction pattern with characteristic peaks at specific reflection angles. The method involves administering a therapeutically effective amount of this polymorph Form I to the subject in need, with the requirement that it is predominantly free of other forms, ranging from at least 70% to 99%.
Furthermore, the patent also covers the administration of the polymorph Form I of ST-246 for treating eczema vaccinatum specifically. The method involves administering this specific form of ST-246 orally to patients suffering from eczema vaccinatum, a severe and potentially life-threatening complication of smallpox vaccination. The polymorph Form I used in this treatment exhibits the same distinct X-ray powder diffraction pattern as mentioned earlier, ensuring the therapeutic efficacy of the treatment. This patent highlights a novel approach to treating Orthopoxvirus infections and eczema vaccinatum by utilizing a specific polymorph Form I of ST-246 with defined characteristics.
To know more about GlobalData’s detailed insights on SIGA Technologies, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
